Indian Drug-Makers Expect Minimal Hit To Generics, May Plan Change In Business Strategy Amid Trump Tariff Risks

Indian Drug-Makers Expect Minimal Hit To Generics, May Plan Change In Business Strategy Amid Trump Tariff Risks

Industry insiders believe a combination of legal preparedness, domestic policy support, and strategic market realignment is essential for Indian pharma companies to remain globally competitive